Sumo: Your prediction about next week makes sense that the stock should get hammered. That is plausible, because of the late filing. However, what makes sense and what actually happens isn't always the same thing.
I think there are investors that are motivated to not let the stock price drop below .06 cents, as Solantey has mentioned. And, I think there are a lot of shareholders who think the .064 to .066 range is an excellent buy. And, I think shorts must be worried about what catalysts Gerald may have on hand once this late filing is resolved.
So, while you might think the stock price craters this next week, it may not. There might be significant buying that doesn't allow it to stay much below .07 for very long. Remember, we've had 2 independent researchers both say that MANF successfully treats Diabetes in mice. That is very significant. And, we have other major catalysts as well.
Personally, I think the trading will be a little "iffy" for a few days until we get this behind us. Then I think we'll find solid ground and Gerald will crank up the positive news. I still think we'll trade above .10 cents in May. (Diabetes Data alone will do that. A partnership sends us....who knows how high!)
Eltoprazine news is coming soon: Grants from MJFF, Beginning of Phase 2b trial. This will go nicely with the Diabetes news. So I'd be careful with any panic selling Monday.
News 
Market Data 
Discover 
AI
